BioInvent's anti-oxLDL well tolerated in Ph I trial
Lund, Sweden-based BioInvent International AB says that its therapeutic antibody product candidate BI-204 (anti-oxLDL) has reached the primary endpoint in a Phase I trial, and was safe and well tolerated. The firm is currently deciding whether to progress to Phase II.
In the trial, pharmacokinetic results showed that the half life was in the expected range for fully-human antibodies. The study, conducted in Denmark, involved a total of 80 healthy patients with elevated low-density lipoprotein cholesterol. The drug is being co-developed with Genentech, a wholly-owned unit of Swiss drug major Roche, under an agreement signed in January 2007.
Genentech owns commercialization rights for North America, while BioInvent has retained the rights for the rest of the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze